Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Avingtrans 570p £203.41m (AVG.L)</li>
<li>The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors announced a trading update regarding the financial year ended 31 May 2026.</li>
<li>The Board reported that profit for the Period will be in line with market expectations and the Group has continued to secure strategically significant contract awards across its core nuclear and infrastructure markets, while also making encouraging progress in expanding its presence in adjacent growth sectors.</li>
</ul>


Avingtrans 570p £203.41m (AVG.L)
The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors announced a trading update regarding the financial year ended 31 May 2026.
The Board reported that profit for the Period will be in line with market expectations and the Group has continued to secure strategically significant contract awards across its core nuclear and infrastructure markets, while also making encouraging progress in expanding its presence in adjacent growth sectors.


Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Avingtrans is an engineering group executing a disciplined 'Pinpoint-Invest-Exit' strategy, focusing on acquiring and growing businesses in highly regulated niche markets such as energy, medical, and industrials.</li>
  <li>The Advanced Engineering Systems (AES) division, particularly its exposure to the nuclear energy sector (decommissioning, life extension, and next-gen reactors), is a primary driver of revenue and profitability, supported by strong order books.</li>
  <li>The Medical and Industrial Imaging (MII) division offers significant long-term growth potential through its development of innovative, compact, helium-free MRI and 3D X-ray systems, though it currently represents a smaller portion of the business.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Avingtrans is an engineering group executing a disciplined 'Pinpoint-Invest-Exit' strategy, focusing on acquiring and growing businesses in highly regulated niche markets such as energy, medical, and industrials.
  The Advanced Engineering Systems (AES) division, particularly its exposure to the nuclear energy sector (decommissioning, life extension, and next-gen reactors), is a primary driver of revenue and profitability, supported by strong order books.
  The Medical and Industrial Imaging (MII) division offers significant long-term growth potential through its development of innovative, compact, helium-free MRI and 3D X-ray systems, though it currently represents a smaller portion of the business.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Avingtrans plc (AVG LN) - Jan 2026

Fundamental Analyses, Contrarian Cashflows

Contrarian Cashflows

Fundamental Analyses

The purpose of Contrarian Cashflows is to document my investment research and share it with everyone who is interested in value investing. My long term aspiration for Contrarian Cashflows is to become a platform for professional investors and serious amateurs where they can get inspiration and discuss investing-related topics.
I plan to publish one company deep dive per month that is guided by my investment approach. All information I use for my write-ups is publicly available and most of the time directly sourced from public filings issued by the respective companies. To guarantee maximum transparency, for every post I provide a list of all used sources in the resources section.
Contrarian Cashflows is built around the principles of respect, honesty, open-mindedness and a touch of humour. Please consider these principles in any engagement interaction with me, other readers and the content on this blog. Misbehaviour is not tolerated.
If you want to reach out to me directly, the best way is via LinkedIn, Twitter or email. You can find the details at my homepage contrariancashflows.com

Thematic (Sector/Industry)

<ul><li>Each week, I’ll share five intriguing investment ideas that recently caught my attention.</li><li>These ideas are meant to spark your research and help you kickstart the week ahead with fresh insights.</li><li>Because these ideas are the result of my first-level idea generation process, they require more in depth research. Therefore, the ideas will often be concise, with occasional references to valuable work from other practitioners that I encourage you to explore.</li></ul>

Each week, I’ll share five intriguing investment ideas that recently caught my attention.These ideas are meant to spark your research and help you kickstart the week ahead with fresh insights.Because these ideas are the result of my first-level idea generation process, they require more in depth research. Therefore, the ideas will often be concise, with occasional references to valuable work from other practitioners that I encourage you to explore.

<ul>
<li>The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.</li>
<li>This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.</li>
<li>Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. </li>
</ul>


The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.
This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.
Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. 


<ul>
<li>Abingdon Health 7.75p £18.20m (ABDX.L) The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected value of approximately US$2m.</li>
<li>The Company has signed a Master Service Agreement (MSA) with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system.</li>
<li>The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. </li>
</ul>


Abingdon Health 7.75p £18.20m (ABDX.L) The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected value of approximately US$2m.
The Company has signed a Master Service Agreement (MSA) with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system.
The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. 


Hybridan Small Cap Feast: 10 November 2025

United Kingdom

Avingtrans designs, manufactures, and supplies engineered components, systems, and associated aftermarket services to the energy, medical, and industrial markets worldwide. The company's products include electric motors, pumps, turbines, gas compressors, pressure vessels, and blast doors. It also provides equipment for medical diagnostic systems, such as 3D X-ray systems and superconducting magnets for MRI. Avingtrans plc was incorporated in 1985 and is based in Chatteris, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avingtrans (AVG LN)

Hybridan Small Cap Feast: 24 June 2026

The Company which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and...

Hybridan

Primer: Avingtrans plc (AVG LN) - Jan 2026

Avingtrans is an engineering group executing a disciplined 'Pinpoint-Invest-Exit' strategy, focusing on acquiring and growing businesses in...

αSK Primers

Monday Delight: 04/05/2026

Each week, I’ll share five intriguing investment ideas that recently caught my attention. These ideas are meant to spark your research and help...

Contrarian Cashflows

Hybridan Small Cap Feast: 26 March 2026

The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.

Hybridan

Hybridan Small Cap Feast: 10 November 2025

The international developer, manufacturer, and distributor of high quality and effective rapid tests announces a new contract win with an expected...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)